Cormorant Asset Management PHVS Position
Active8-Fund ConvergenceCormorant Asset Management trimmed their position in Pharvaris N.V. (PHVS) in Q4 2025, holding $30.1M worth of shares across 1,083,000 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
PHVS is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Full company profile →Short Interest
1.4%
6.0 days to cover
Cormorant Asset Management PHVS Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 1,083,000 | -280,200 | $30.1M |
| Q3 2025 | Decreased | 1,363,200 | -91,460 | $34.0M |
| Q2 2025 | Decreased | 1,454,660 | -11,800 | $25.6M |
| Q1 2025 | Held | 1,466,460 | — | $23.0M |
| Q4 2024 | Held | 1,466,460 | — | $28.1M |
| Q3 2024 | Held | 1,466,460 | — | $27.2M |
| Q2 2024 | Decreased | 1,466,460 | -245,000 | $27.6M |
| Q1 2024 | Held | 1,711,460 | — | $39.6M |
| Q4 2023 | Increased | 1,711,460 | +350,000 | $48.0M |
| Q3 2023 | Increased | 1,361,460 | +387,846 | $28.4M |
| Q2 2023 | Increased | 973,614 | +157,154 | $14.7M |
| Q1 2023 | New | 816,460 | +816,460 | $6.6M |
Frequently Asked Questions
Does Cormorant Asset Management own PHVS?
Yes. As of Q4 2025, Cormorant Asset Management holds 1,083,000 shares of Pharvaris N.V. (PHVS) valued at $30.1M. This data comes from their SEC 13F filing.
How many hedge funds own PHVS?
8 specialist biotech hedge funds currently hold PHVS, including Foresite Capital, Deerfield Management, Commodore Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy PHVS?
Cormorant Asset Management's position in PHVS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's PHVS position increasing or decreasing?
Cormorant Asset Management trimmed their PHVS position in the most recent quarter, reducing by 280,200 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PHVSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →